ClinicalTrials.gg
CompletedNCT01384435Updated Dec 3, 2012

A Phase II Double Blind Comparative Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

A Phase 2 interventional study of KPS-0373 and KPS-0373 in SCD, sponsored by Kissei Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2012-12-03.

Sponsored by Kissei Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Spinocerebellar Degenerations with a site in Japan — none open to participants now, 1 under way, 1 of them phase 3. Spinocerebellar Degenerations · Japan.

Phase 2
4 of 11
none open now
Registered
3rd of 11
by date
Lead sponsor
9 of 11
Kissei Pharmaceutical Co., Ltd.

Among the 11 studies in Spinocerebellar Degenerations with a site in Japan, this one is one of 4 in phase 2, and was the 3rd registered.

Spinocerebellar Degenerations

49 studies on the registry are indexed under Spinocerebellar Degenerations; 15 are open to participants now.

Browse Spinocerebellar Degenerations studies →

Open to participants now

None of the 11 studies in Spinocerebellar Degenerations with a site in Japan is open now. The open studies under Spinocerebellar Degenerations, anywhere →

Who these studies take

Of the 9 Spinocerebellar Degenerations studies recruiting now, 5 set no upper age limit and 3 stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Spinocerebellar Degenerations with a site in Japan as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of KPS-0373 compared to placebo in patients with Spinocerebellar Degeneration (SCD).

03

Conditions studied

  • SCD

Keywords

  • Spinocerebellar degeneration (SCD)
  • Thyrotropin-Releasing Hormone (TRH)
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Japanese SCD patients with mild to moderate ataxia

Exclusion criteria

Exclusion Criteria:

  • Patients with secondary ataxia
  • Patients with hepatic, renal, or cardiovascular dysfunction
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    KPS-0373, lowest dose

    Drug: KPS-0373

  • Experimental
    KPS-0373, 2nd lowest dose

    Drug: KPS-0373

  • Experimental
    KPS-0373, 2nd highest dose

    Drug: KPS-0373

  • Experimental
    KPS-0373, highest dose

    Drug: KPS-0373

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline in Scale for the assessment and rating of ataxia (SARA)

    Time frame: 24 weeks

Secondary outcomes

  1. Change from baseline in patient improvement impression of activities of daily living

    Time frame: 24 weeks

07

Study locations

1 site
  • Japan
    Tokyo and Other Japanese City, Japan
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 3, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01384435
First posted
Jun 29, 2011
Last update
Dec 3, 2012

Study contacts

Katsumi Hontani
study director · Clinical Research Dept.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rovatirelin

Start the discussion